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A b s t r a c t
Introduction: Metabolic Syndrome Severity Score (MSSS) is a new clinical 
prediction rule (CPR) for diagnostic and therapeutic decisions and employs 
available components (sex, age, race, systolic blood pressure, waistline cir-
cumference, high-density lipoprotein, triglycerides and fasting blood glucose). 
The aim of our work was to perform cross-sectional pilot trial on middle-aged 
healthy volunteers and patients with metabolic syndrome (MetS) with and 
without type 2 diabetes mellitus (T2DM) for studying feasibility and imple-
mentation of MSSS and its associations with cardiovascular risk factors.
Material and methods: We approached 64 eligible participants from Bulgar-
ia. The MSSS values, together with demographic, anthropometric, medical 
history, laboratory findings, CVD risk factors, QRISK2 score for 10-year car-
diovascular risk and predicted heart age, were analysed. Descriptive statis-
tics with tests for comparison (e.g., t-test, c2) between groups as well as 
ANOVA and logistic regression were applied.
Results: We analysed data from 56 participants (aged 50.11 ±3.43 years). 
The MSSS was higher in MetS patients (including 6 T2DM patients) than in 
controls (n = 29; 51.8%) presented as percentiles (69.97% and 34.41%, re-
spectively) and z-scores (0.60 and –0.45, respectively) (p < 0.05). The logistic 
regression model of MSSS indicated a positive association with MetS/T2DM 
cases (correctness > 85%, p < 0.01). For further validation purposes, positive 
correlations of MSSS with CVD risk factor as diastolic blood pressure (Rho 
= 0.399; p < 0.003) and QRISK2 score (Rho = 0.524; p < 0.001) or predicted 
heart age (Rho = 0.368; p < 0.007) were also found.
Conclusions: The pilot study of MSSS in Bulgaria indicated feasibility and 
consistency of its implementation among patients with metabolic syndrome 
and/or T2DM and healthy volunteers.
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Introduction
The metabolic syndrome (MetS) represents a complex disease entity 
of mutually related pathological symptoms, signs and risk factors (dys-
glycaemia, dyslipidaemia, arterial hypertension and obesity of visceral 
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type) for development of type 2 diabetes melli-
tus (T2DM) and cardiovascular diseases (CVD) 
[1]. The classification of MetS in two clinical 
groups depending on the presence or absence 
of T2DM additionally widens the problem in con-
sideration of the large variability of microvascu-
lar pathologies such as retinopathy, neuropathy 
and nephropathy [2, 3]. This concept of MetS as 
a two-facet entity (ICD-10-CM Code E88.81 Met-
abolic syndrome) appears to be a very important 
clinical tool for the assessment of the risk of CVD 
and T2DM. According to a  number of longitudi-
nal studies, when MetS is present, the CVD risk 
is increased two-fold [4], while the T2DM risk is 
increased up to 4-fold [5].
The increasing incidence and prevalence of 
MetS worldwide (> 20% among the adult popu-
lation) [6] determine its major health, social and 
economic importance. Defining better the severity 
of MetS might represent a core aspect of a suc-
cessful clinical approach for estimation of the risk 
of T2DM [5] and CVD [4]. The frequency of MetS in 
Bulgaria is 26.8% if defined by only 3 components 
(CVD risk factors) and further increases if defined 
by 4 such possible components (by 6%) [7]. Anoth-
er study has reported a prevalence of about 30.8% 
of MetS [8].
The diagnostic (reference) criteria for MetS are 
a combination of results from routine clinical and 
laboratory tests – systolic blood pressure, waist 
circumference, high-density lipoproteins (HDL) 
cholesterol, triglycerides and fasting blood glu-
cose levels, according to the International Diabe-
tes Federation (IDF). They are closely related to 
other parallel metabolic states and processes such 
as insulin resistance, oxidative stress and chronic 
inflammation, which, on their own, may also be 
considered as predictors of CVD (e.g., hsCRP) [9, 
10]. However, some of the imperfections of the 
above diagnostic criteria lie in their binary nature 
(presence/absence) which does not allow for an 
exact estimation of the risk when marginal values 
are considered. Such borderline values may carry 
a hidden cardio-metabolic risk, as we had shown 
earlier for marginally increased homocysteine lev-
els (still within the “normally” accepted range) 
and increased but “hidden” risk of ischaemic 
stroke in younger patients [11]. Similarly, we have 
identified new cut-off points based on predicted 
risk of outcome events that were below or above 
the previously accepted normal (reference) values 
of the predictors [12, 13] – in many cases such 
cut-offs are very useful in practice and may be 
easily incorporated into diagnostic or treatment 
algorithms. Unfortunately, in the case of the MetS 
components, such binary nature allows neither 
a diagnosis of MetS (when the diagnostic criteria 
are increased, or even borderline, but still below 
the accepted normal reference values) nor an ad-
equate estimation of the severity of the underly-
ing pathological processes. To solve this duality 
some authors have suggested in such situations 
the use of a continuous range of values [14, 15] 
which form a scale of severity of MetS. Many au-
thors have proposed different methods for calcu-
lation of such continuous scales in adults [16, 17] 
as well as in children and teenagers [18–20]. The 
authors used different statistical methods to de-
rive such scales as principal component analysis 
[16, 20–22] and the method of percentiles [23]. 
For our current study we applied the most recently 
suggested scale, called the metabolic syndrome 
severity score (MSSS), which can be calculated 
as a z-score as well as in percentiles. The score is 
based on both clinical and anthropometric char-
acteristics.
The aim of our study was to perform a pilot ap-
plication of MSSS to analyse its feasibility, range 
and associations with CVD risk factors among 




We approached 64 consecutive volunteers from 
the Clinic of Endocrinology and Clinic of Neurology, 
Medical University Hospital “St George”, Plovdiv, 
who were seen during the period from October 
2014 to October 2015. The study was approved 
by the Ethical Committee of the Medical Faculty. 
The inclusion criteria were: age 45–55 years, with 
normal daily living. The exclusion criteria were: 
history of cardiovascular or cerebrovascular acci-
dents (e.g., heart attack, TIA, stroke), traumatic, 
degenerative or inflammatory diseases of the ner-
vous system; epilepsy, other endocrine disorders 
(except T2DM) or medications which could have 
had metabolic effects.
Clinical and laboratory investigations
The participants who agreed to participate and 
provided written informed consent (according to 
the Declaration of Helsinki guidelines) were sub-
jected to further interview and physical (includ-
ing anthropometric), neurological and laboratory 
investigations. Laboratory tests: blood tests by 
Coulter STKS (USA); tests for glucose, urea, creat-
inine, total and HDL cholesterol, triglycerides and 
liver enzymes (Konelab 60i, Finland). According 
to the questionnaire on disease history, CVD risk 
factors and laboratory tests the volunteers were 
divided into two groups: 32 cases of patients with 
the diagnosis of metabolic syndrome (MetS, at 
least 3 components present according to current 
IDF criteria) and 32 controls without MetS (al-
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though with 1 or 2 CVD risk factors). Out of 32 ca- 
ses with MetS, 6 cases had T2DM. 
Clinical prediction rules (CPRs)
The clinical scales, or rules, for evaluation of 
CVD risk and associated pathologies and events 
were calculated using free online calculators. The 
10-year CVD risk was assessed by the QRISK2 
score, provided by the University of Nottingham, 
UK [24] at http://www.qrisk.org/. The predicted 
heart/vascular age was calculated by using data 
on the lipid profile according to the equation from 
the Framingham study in the USA [25] (Cardio-
vascular Disease (10-year risk) – interactive risk 
score calculator using lipids at www.framingham-
heartstudy.org/risk-functions/cardiovascular-dis-
ease/10-year-risk.php#). These estimates helped 
us to evaluate the potential risk of future CVD 
events for all participants. 
Metabolic syndrome severity score (MSSS): 
MSSS calculation was performed with the online 
tool “METS Severity Calculator” at http://public- 
health.hsc.wvu.edu/biostatistics/metabolic-syn-
drome-severity-calculator/mets-severity-calcula-
tor/ [20]. The equations for calculation of MSSS are 
based on the NHANES study in the USA with the 
following arguments: age, race, gender, waist cir-
cumference, triglycerides (TGL), high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein 
(LDL) cholesterol, systolic blood pressure (SBP) and 
blood glucose levels [20]. The MSSS was calculated 
in two variants: (i) z-score (from minus to plus in-
finity) with zero (0) indicating the average severity, 
and (ii) percentiles (0–100%), which can be inter-
preted as the growth percentiles in children.
Statistical analysis
This study was performed as a cross-sectional, 
case-control proof-of-concept trial to establish the 
prevalence of MetS, T2DM, CVD risk factors and 
range of MSSS and other CPRs and association 
within a pilot sample of the Bulgarian population. 
Since there were only 6 patients with T2DM, these 
were initially described as a separate sub-group, 
but they were later combined with those having 
only MetS to form the two main outcome popu-
lations in our study: MetS/T2DM patients (cases) 
and healthy volunteers (controls). Given the pilot 
nature of the study, no a priori power and sample 
size calculations were performed, but a  conve-
nience sample of consecutive eligible participants 
was used.
Data were analysed by descriptive statistics 
presented as frequency (percent) for the categor-
ical variables and mean with standard deviation 
and 95% CI for the continuous variables, as appro-
priate. Normality of distributions of the continu-
ous variables was tested by the Shapiro-Wilk test. 
The comparisons were made by parametric and 
non-parametric methods (t-test, Mann-Whitney 
test) as well as analysis of variance (ANOVA) or 
c2 and Fisher’s exact test for categorical data. As-
sociations were tested by odds ratio (OR) and its 
95% CI and parametric (Pearson) or non-paramet-
ric (Spearman) correlations, as appropriate. Uni-
variable or multivariable logistic regression anal-
yses were applied to predict outcome as based on 
MSSS as adjusted for one or more possible con-
founders. P-value < 0.05 was considered statisti-
cally significant. All analyses were performed by 
the statistical software packages SPSS and SAS.
Results
Patients’ characteristics
The main demographic, medical history, clinical 
and laboratory features of all patients and controls 
included in the analyses are summarised in Table I. 
From all approached 64 eligible participants, 8 par-
ticipants dropped out (5 patients and 3 controls) 
as they did not provide informed consent (Fig- 
ure 1). Therefore, 56 participants were included in 
the analyses in two outcome groups: 29 (51.8%) 
healthy volunteers aged 50.59 ±3.41 years (6 men, 
20.7%; 23 women, 79.3%) and 27 (48.2%) patients 
with MetS/T2DM aged 49.59 ±3.43 years (13 men, 
48.1%; 14 women, 51.9%) including 6 patients 
with T2DM. The frequency was 48.2% (95% CI: 
35.1–61.3). No differences were found except for 
gender, with a predominating proportion of female 
participants among controls.
Associations of MSSS with MetS/T2DM
All risk factors and components of MetS were 
different, understandably, between the cases and 
controls (p < 0.05). As mentioned earlier, 6 (22.2%) 
of the patients with MetS also had T2DM. Also, 
the additionally estimated 10-year CVD risk was 
almost double in cases (7.90%) compared to con-
trols (3.79%); the predicted heart age was also 
higher in the cases (65.08 years) than in controls; 
all differences at p < 0.01. 
In particular, the newly developed rule MSSS 
also had higher, more risky mean values among 
the cases (p < 0.01) in its both variants (z-score 
and percentiles), i.e., 0.60 and 69.97%, respective-
ly (Table I). This first important validating pattern is 
very well illustrated in Figure 2, where it also very 
well seen that the significant overall difference in 
MSSS z-score between the two groups (Figure 2 A) 
is due not only to the difference between healthy 
controls (n = 29) and T2DM patients (n = 6), 
but also to the significant difference compared to 
the patients with MetS alone (n = 21) (Figure 2 B, 
p
ANOVA < 0.001).
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Table I. Main socio-demographic, medical history and clinical characteristics
Characteristics [units]* Healthy volunteers  
(controls)
Patients with MetS  
and/or T2DM (cases)* 
Total
Number (%) 29 (51.8) 27 (48.2) 56 (100)
Gender (M/F)# 6 (20.7)/23 (79.3) 13 (48.1)/14 (51.9) 19 (33.9)/37 (66.1)
Age 50.59 ±3.41 49.59 ±3.44 50.11 ±3.43
Education (secondary/higher) 5 (17.2)/24 (82.8) 8 (29.6)/19 (70.4) 13 (23.2)/43 (76.8)
Smoking (no/ex-smoker/yes) 13 (46.4)/7 (25.0)/8 (28.6) 11 (20.4)/7 (13)/8 (14.8) 24 (24.4)/14 (25.9)/16 (29.6)
Medications (no/yes) 6 (75)/2 (25) 3 (25)/9 (75) 9 (45)/11 (55)
Family history (no/yes)# 4 (44)/5 (55.6) 0 (0)/12 (100) 4 (19)/17 (81.0)
Family predisposition (mother/
father)
5 (100)/0 (0) 9 (75)/3 (25) 14 (82.4)/12 (70.6)
Diseases – main vascular risk factors:
Cardiovascular disease (CVD) 
(no/yes)#
20 (71.4)/8 (28.6) 11 (42.3)/15 (57.7) 32 (57.4)/23 (42.6)
Type 2 diabetes mellitus 
(T2DM) (no/yes)$
28 (100)/0 (0) 20 (76.9)/6 (23.1) 48 (88.9)/6 (11.1)
Dyslipidaemia (DLP) (no/yes)# 22 (81.5)/5 (18.5) 14 (53.8)/12 (46.2) 36 (67.9)/17 (32.1)
Peripheral vascular disease 
(PVD) (no/yes)
25 (89.3)/3 (10.7) 24 (92.3)/2 (7.7) 49 (90.7)/5 (9.3)
Hypertension (HT) (no/yes)$ 28 (100)/0 (0) 10 (40)/15 (60) 37 (71.7)/15 (28.3)
Other diseases (no/yes) 17 (81)/4 (19) 13 (72.2)/5 (27.8) 30 (76.9)/9 (23.1)
Components of the metabolic syndrome:
HDL < 1 mmol/l (men)  
or HDL < 1.29 mmol/l (women) 
or on treatment (no/yes)$
25 (86.2)/4 (13.8) 10 (37)/17 (63.0) 35 (62.5)/21 (37.5)
TGL > 1.7 mmol/l and/ 
or on treatment (no/yes)$
 28 (96.6)/1 (3.4) 7 (25.9)/20 (74.1) 35 (62.5)/21 (37.5)
Blood glucose > 5.6 mmol/l 
and/or on treatment/T2DM 
(no/yes)$
19 (65.5)/10 (34.5) 8 (29.6)/19 (70.4) 27 (48.2)/29 (51.8)
SBP > 130 or DBP > 85  
and/or on  
anti-hypertensive therapy  
(no/yes)$*
28 (96.6)/1 (3.4) 11 (40.7)/16 (59.3) 39 (69.6)/17 (30.4)
Waist circumference  
> 94 cm (men) or > 80 cm 
(women) (no/yes)#
11 (37.9)/18 (62.1) 3 (11.1)/24 (88.9) 14 (25)/42 (75)
Predicted heart age [years]$* 52.14 ±9.43 65.08 ±12.83 58.37 ±12.86
QRISK index (10-year CVD risk 
indicator) [%]$*
3.79 ±2.41 7.90 ±7.38 5.78 ±5.75
Metabolic syndrome severity 
score (MSSS) (z-score)$*
–0.45 ±0.51 0.60 ±0.57 0.059 ±0.76
Metabolic syndrome severity 
score (MSSS) [percentiles]$*
34.41 ±16.62 69.97 ±17.13 51.56 ±24.51
*MetS/T2DM – metabolic syndrome/type 2 diabetes mellitus; number (percent) or mean (standard deviation); the category “Yes” means 
the presence of the characteristics or symptom or positive (pathological) results from a  diagnostic test/procedure; #p < 0.05 or $p < 
0.01 indicates significant difference between cases and controls as based on c2 test or Fisher’s exact test; the quantitative variables are 
compared by the non-parametric Mann-Whitney test; the predicted heart age (years) is calculated according to the models from the 
Framingham study in the USA (see text for more details); the index of 10-year cardiovascular risk (QRISK) is calculated according to the 
model equation provided by the University of Nottingham in England (see text for more details). 
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The above findings, in terms of a possible re-
lationship between MSSS and MetS/T2DM (out-
come) as a further, second validating characteris-
tic for this newly developed rule, were assessed by 
a  logistic regression model. The model indicated 
a very strong and significant positive relationship 
(Figure 3 A) of increasing probability of the out-
come with increasing values of the MSSS z-score 
(p < 0.001, correct classification > 85%); when the 
relationship was adjusted for gender, interesting 
differing patterns of this relationship were ob-
served for males and females, although gender 
was not found to be significant as a covariate (p = 
0.272) (Figure 3 B).
Further confirmation of the above finding was 
also the association of each individual risk factor 
and MetS component by the odds ratio (OR) and, 
where this was not possible, by the c2 or Fisher’s 
exact test only (Table II). Clearly, the CVD risk fac-
tors are more frequent and with higher, more risky 
levels in the cases with MetS/T2DM than in the 
healthy controls. 
Associations of MSSS with CVD risk factors
The establishment of higher MSSS values in 
Bulgarian patients with MetS/T2DM, including 
the statistically significant differences from Bul-
garian controls (i.e., among a  population that is 
different from that in the USA where the MSSS 
was initially derived and all initial relationships 
were first described), is one of the main elements 
in the process of validation of the new score for 
severity of the metabolic syndrome in another 
country, i.e., Bulgaria. Since it is well known that 
MetS and its severity, or progression, are import-
ant CVD risk factors, the third way by which such 
a continuous score may be validated further is to 
confirm statistically significant correlations with 
MetS components which had not been used in 
Figure 1. CONSORT-like flow-chart of study design, enrolment and analysis
Patients with MetS and/or T2DM (cases) (n = 32)
All identified participants (n = 64)
Healthy volunteers (controls) (n = 32)
Participants completing the study (n = 56)
Not completing the study (n = 8)
Patients with MetS and/or T2DM (cases) (n = 5) Healthy volunteers (controls) (n = 3)
Patients with MetS and/or T2DM (cases) (n = 27) Healthy volunteers (controls) (n = 29)
Figure 2. Metabolic syndrome severity score (MSSS) comparisons between healthy controls and patients with 
MetS/T2DM. A – Box-plots, illustrating the differences of MESS (z-score) between healthy controls and patients. 
Median, interquartile range (IQR) and the end-point values within 1.5 times IQR are indicated by the middle 
horizontal line, lower and upper box lines and whiskers, respectively. B – Results from ANOVA of the comparison 
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Table II. Associations of socio-demographic, medical history and clinical characteristics with the presence of met-
abolic syndrome and/or type 2 diabetes mellitus
Characteristics/risk factors Categories Frequency  
of MetS/T2DM in 
each category (%)
Odds ratio, OR (p)*
Gender Female/male 37.8/68.4 0.281 (p = 0.030)
Education Higher/secondary 44.2/61.5 0.495 (p = 0.273)
Smoking No/ex-smoker/yes 45.8/50.0/50.0 – (p = 0.955)
Medications Yes/no 81.8/33.3 9.00 (p = 0.065)#
Family history Yes/no 70.6/0.0 – (p = 0.021)#
Family predisposition (parents) Mother/father 64.3/100 – (p = 0.515)#
Diseases – main vascular risk factors:
Cardiovascular disease (CVD) Yes/no 65.2/35.5 3.409 ( p = 0.031)
Dyslipidaemia (DLP) Yes/no 70.6/38.9 3.771 (p = 0.031)
Peripheral vascular disease (PVD) Yes/no 40.0/49.0 0.694 (p = 0.99)#
Hypertension (HT) Yes/no 100.0/26.3 – (p = 0.001)#
Components of the metabolic syndrome**:
HDL < 1.00 mmol/l (men) or  
HDL < 1.29 mmol/l (women) or on treatment 
Yes/no 81.0/28.6 10.625 (p < 0.001)#
TGL > 1.7 mmol/l or on treatment Yes/no 95.2/20.0 80.000 (p < 0.001)#
Blood glucose > 5.6 mmol/l or  
on treatment/T2DM 
Yes/no 65.5/29.6 4.513 (p < 0.007)
SBP > 130 or DBP > 85 and/or  
on anti-hypertensive therapy**
Yes/no 94.1/28.2 40.727 (p < 0.001)#
Waist circumference > 94 cm (men)  
or > 80 cm (women)
Yes/no 57.1/21.4 4.889 (p < 0.030)#
OR, the statistical significance was determined by *c2 test or #Fisher’s exact test, was not calculated for the characteristics with null 
events or more than two categories; **Defined according to the guidelines of the Bulgarian Institute for Metabolic Syndrome and 
International Diabetic Federation, MetS – metabolic syndrome, T2DM – type 2 diabetes mellitus, HDL – high-density lipoprotein, 
TGL – triglycerides, SBP – systolic blood pressure, DBP – diastolic blood pressure.
Figure 3. Logistic regression models of cases with MetS/T2DM and MSSS in all 56 participants. A – Probability of 
MetS/T2DM expressed as a nonlinear relationship along the MSSS (z-score) range (pmodel < 0.001). X-axis, MSSS 
(z-score); Y-axis, probability of MetS/T2DM (where 0.00 = no MetS/T2DM; 1.00 = MetS/T2DM) at cut-off probabil-
ity of 0.50. B – Probability of MetS/T2DM expressed as a nonlinear relationship along the MSSS range, adjusted 
for gender (pmodel < 0.001). X-axis, MESS (z-score); Y-axis, probability of MetS/T2DM (where 0.0 = no MetS/T2DM;  
1.0 = MetS/T2DM) at cut-off probability of 0.5. Male, blue curve (steeper relationship); female, red curve (more 
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Figure 4. Linear relationship between diastolic 
blood pressure and MSSS. X-axis, diastolic blood 
pressure; Y-axis, MSSS (z-score); circles, individual 
values; diagonal line, best fitting regression model 
line; curves, 95% confidence intervals; R2 is for illus- 
trative purposes only (see text for more details)
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          Diastolic blood pressure [mm Hg]



























Figure 5. Linear relationship of MSSS with predicted heart age and QRISK2 index. A – X-axis, predicted heart age; 
Y-axis, MSSS (z-score); circles, individual values; diagonal line, best fitting regression model line; curves, 95% con-
fidence intervals; R2 is for illustrative purposes only (see text for more details); B – X-axis, QRISK2 index (%); Y-axis, 
MSSS (z-score); circles, individual values; diagonal line, best fitting regression model line; curves, 95% confidence 
intervals; R2 is for illustrative purposes only (see text for more details)
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the calculation of MSSS, other known CVD risk 
factors or validated CVD clinical prediction rules. 
In fact, as a third validating pattern, we revealed 
such positive correlations between MSSS and: 
(i) diastolic blood pressure (DBP) – RhoSpearman = 
0.399 (p < 0.003, Figure 4); (ii) predicted heart age 
(Rho = 0.368, p < 0.007); and (iii) QRISK2 score – 
Rho = 0.524 (p < 0.001, Figure 5). 
In this sense, as another albeit secondary con-
firmatory pattern, we can present the significant 
correlation between the predicted heart age and 
the calendar age (RhoSpearman = 0.381, p < 0.005, not 
shown). We have to underline that the predicted 
heart age (mean = 58.4) is higher by about 8.2 
years (p < 0.001) than the mean calendar age of 
all participants (50.11, Table I) despite the fact that 
both cases and controls had the same mean calen-
dar age.
Discussion
Our present work has applied the new MSSS, 
as developed in the USA, for the first time in Bul-
garia. In their longitudinal study in 2015, Vishnu 
and co-authors reported a predictive accuracy of 
80% for MSSS [14]. The calculated MSSS showed 
a  positive correlation with the development of 
cardiovascular diseases or CVD-related outcomes 
and procedures (myocardial infarction, heart sur-
gery, bypass, stroke) later in life [21]. Higher basic 
values were related to earlier age of CVD incidents 
(mean of 38 years) [26].
The clinical prediction rule, MSSS, by Gurka et al. 
[20] has been applied in our pilot study in Bulgaria 
and indicated significantly higher values in the 27 
(48.2%) patients with MetS/T2DM. It has proved 
to be feasible for application in a clinical setting for 
screening purposes and reliable in terms of consis-
tency of the results: higher levels indicated higher 
probability of presence of MetS/T2DM (Figure 3 A), 
and there was a positive correlation of MSSS with 
both the predicted heart rate and QRISK score for 
10-year cardiovascular risk.
In conclusion, we may consider that our pilot 
implementation in Bulgaria of the newly developed 
American score for MSSS is successful and has 
shown its feasibility, ease of use and consistency 
in terms of range and directions of the significant 
associations with MetS/T2DM and related CVD 
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risk factors. These results are original for Bulgaria 
and also presented the MSSS distribution among 
healthy volunteers, which may serve as the basis of 
further, large studies to establish normal, references 
standards for the Bulgarian population. The above 
findings may also be used for planning further trials 
for wider, prospective validation and impact analy-
sis of MSSS in Bulgaria and, if necessary, for its fur-
ther calibration, modification and updating.
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